Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,956 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.
Chi KN, Yu EY, Jacobs C, Bazov J, Kollmannsberger C, Higano CS, Mukherjee SD, Gleave ME, Stewart PS, Hotte SJ. Chi KN, et al. Among authors: jacobs c. Ann Oncol. 2016 Jun;27(6):1116-1122. doi: 10.1093/annonc/mdw068. Epub 2016 Feb 18. Ann Oncol. 2016. PMID: 27022067 Free article. Clinical Trial.
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM, Mukherjee SD, Zalewski P, Saad F, Jacobs C, Gleave M, de Bono JS. Chi KN, et al. Among authors: jacobs c. Lancet Oncol. 2017 Apr;18(4):473-485. doi: 10.1016/S1470-2045(17)30168-7. Epub 2017 Mar 8. Lancet Oncol. 2017. PMID: 28283282 Clinical Trial.
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.
Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP. Bellmunt J, et al. Among authors: jacobs c. Ann Oncol. 2017 Oct 1;28(10):2481-2488. doi: 10.1093/annonc/mdx400. Ann Oncol. 2017. PMID: 28961845 Free article. Clinical Trial.
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K. Beer TM, et al. Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9. Lancet Oncol. 2017. PMID: 29033099 Clinical Trial.
Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL, Qu W, Lin HM, Spielman C, Cain D, Jacobs C, Stockler MR, Higano CS, de Bono JS, Chi KN, Clark SJ, Horvath LG. Mahon KL, et al. Among authors: jacobs c. Eur Urol. 2019 Sep;76(3):306-312. doi: 10.1016/j.eururo.2018.11.001. Epub 2018 Nov 19. Eur Urol. 2019. PMID: 30466891 Clinical Trial.
Cytisinicline for Smoking Cessation: A Randomized Clinical Trial.
Rigotti NA, Benowitz NL, Prochaska J, Leischow S, Nides M, Blumenstein B, Clarke A, Cain D, Jacobs C. Rigotti NA, et al. Among authors: jacobs c. JAMA. 2023 Jul 11;330(2):152-160. doi: 10.1001/jama.2023.10042. JAMA. 2023. PMID: 37432430 Free PMC article. Clinical Trial.
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK. Rosenberg JE, et al. Among authors: jacobs c. Br J Cancer. 2018 May;118(11):1434-1441. doi: 10.1038/s41416-018-0087-9. Epub 2018 May 16. Br J Cancer. 2018. PMID: 29765151 Free PMC article. Clinical Trial.
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
Spigel DR, Shipley DL, Waterhouse DM, Jones SF, Ward PJ, Shih KC, Hemphill B, McCleod M, Whorf RC, Page RD, Stilwill J, Mekhail T, Jacobs C, Burris HA 3rd, Hainsworth JD. Spigel DR, et al. Among authors: jacobs c. Oncologist. 2019 Dec;24(12):e1409-e1416. doi: 10.1634/theoncologist.2018-0518. Epub 2019 Aug 16. Oncologist. 2019. PMID: 31420467 Free PMC article. Clinical Trial.
1,956 results